Tags

Type your tag names separated by a space and hit enter

Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases.

Abstract

Forty older adults with chronic diseases were vaccinated intranasally with either influenza A/California/10/78 (H1N1) (CR37) or influenza A/Washington/897/80 (H3N2) (CR48) virus. No clinically significant morbidity or decrement in pulmonary function occurred postvaccination. Two (15%) recipients of CR37 virus and twelve (44%) recipients of CR48 virus became infected with vaccine virus, as indicated by a fourfold rise in serum hemagglutination inhibition antibody titer; a fourfold rise in serum immunoglobulin G (IgG) or IgA antibody titer, indicated by enzyme-linked immunosorbent assay; isolation of vaccine virus from nasal washings; or all of these. Within 1 year after cold-recombinant vaccine virus vaccination, 18 vaccines received inactivated trivalent influenza virus vaccine parenterally. Of the vaccinees, 13 (72%) developed a fourfold rise in serum antibody titer to H1N1 antigen and 16 (89%) developed a fourfold rise in serum antibody titer to H3N2 antigen. We conclude that administration of these cold-recombinant vaccine viruses to older adults with chronic diseases was safe, but that serum antibody response rates were lower than those achieved with subsequently administered inactivated influenza virus vaccine given parenterally. However, the higher seroconversion rates attained by using the inactivated trivalent influenza virus vaccine do not necessarily mean that it is more efficacious in preventing infection or severe illness or both due to natural wild-type influenza A virus.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors

    , ,

    Source

    Journal of clinical microbiology 24:3 1986 Sep pg 336-42

    MeSH

    Administration, Intranasal
    Adult
    Aged
    Antibodies, Viral
    Chronic Disease
    Clinical Trials as Topic
    Cold Temperature
    Enzyme-Linked Immunosorbent Assay
    Hemagglutination Inhibition Tests
    Humans
    Immunoglobulin A
    Immunoglobulin G
    Influenza A virus
    Influenza Vaccines
    Influenza, Human
    Middle Aged
    Vaccines, Attenuated

    Pub Type(s)

    Clinical Trial
    Controlled Clinical Trial
    Journal Article
    Research Support, U.S. Gov't, Non-P.H.S.
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    3531226

    Citation

    Gorse, G J., et al. "Safety of and Serum Antibody Response to Cold-recombinant Influenza a and Inactivated Trivalent Influenza Virus Vaccines in Older Adults With Chronic Diseases." Journal of Clinical Microbiology, vol. 24, no. 3, 1986, pp. 336-42.
    Gorse GJ, Belshe RB, Munn NJ. Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases. J Clin Microbiol. 1986;24(3):336-42.
    Gorse, G. J., Belshe, R. B., & Munn, N. J. (1986). Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases. Journal of Clinical Microbiology, 24(3), pp. 336-42.
    Gorse GJ, Belshe RB, Munn NJ. Safety of and Serum Antibody Response to Cold-recombinant Influenza a and Inactivated Trivalent Influenza Virus Vaccines in Older Adults With Chronic Diseases. J Clin Microbiol. 1986;24(3):336-42. PubMed PMID: 3531226.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Safety of and serum antibody response to cold-recombinant influenza A and inactivated trivalent influenza virus vaccines in older adults with chronic diseases. AU - Gorse,G J, AU - Belshe,R B, AU - Munn,N J, PY - 1986/9/1/pubmed PY - 1986/9/1/medline PY - 1986/9/1/entrez SP - 336 EP - 42 JF - Journal of clinical microbiology JO - J. Clin. Microbiol. VL - 24 IS - 3 N2 - Forty older adults with chronic diseases were vaccinated intranasally with either influenza A/California/10/78 (H1N1) (CR37) or influenza A/Washington/897/80 (H3N2) (CR48) virus. No clinically significant morbidity or decrement in pulmonary function occurred postvaccination. Two (15%) recipients of CR37 virus and twelve (44%) recipients of CR48 virus became infected with vaccine virus, as indicated by a fourfold rise in serum hemagglutination inhibition antibody titer; a fourfold rise in serum immunoglobulin G (IgG) or IgA antibody titer, indicated by enzyme-linked immunosorbent assay; isolation of vaccine virus from nasal washings; or all of these. Within 1 year after cold-recombinant vaccine virus vaccination, 18 vaccines received inactivated trivalent influenza virus vaccine parenterally. Of the vaccinees, 13 (72%) developed a fourfold rise in serum antibody titer to H1N1 antigen and 16 (89%) developed a fourfold rise in serum antibody titer to H3N2 antigen. We conclude that administration of these cold-recombinant vaccine viruses to older adults with chronic diseases was safe, but that serum antibody response rates were lower than those achieved with subsequently administered inactivated influenza virus vaccine given parenterally. However, the higher seroconversion rates attained by using the inactivated trivalent influenza virus vaccine do not necessarily mean that it is more efficacious in preventing infection or severe illness or both due to natural wild-type influenza A virus. SN - 0095-1137 UR - https://www.unboundmedicine.com/medline/citation/3531226/Safety_of_and_serum_antibody_response_to_cold_recombinant_influenza_A_and_inactivated_trivalent_influenza_virus_vaccines_in_older_adults_with_chronic_diseases_ L2 - http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=3531226 DB - PRIME DP - Unbound Medicine ER -